PROCLAIM Study Fails to Identify Best Regimen for Locally Advanced Lung Cancer

Online First - Lung Cancer, Online First
Alice Goodman

Boston, MA—What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non–small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.

At the 2015 Best of ASCO meeting in Boston, Sarah B. Goldberg, MD, MPH, Assistant Professor of Medicine (Medical Oncology), Yale Cancer Center, New Haven, CT, discussed the results of the study. PROCLAIM compared pemetrexed plus cisplatin and thoracic radiation followed by consolidation with pemetrexed (Arm A) versus etoposide plus cisplatin and thoracic radiation followed by consolidation therapy with etoposide plus cisplatin or the investigator’s choice of doublet (Arm B).

Both regimens are reasonable in locally advanced nonsquamous NSCLC, Dr Goldberg said. “There is no difference in overall survival, and it is doubtful that longer-term follow-up will make a difference. These findings are applicable to many of our patients who are eligible for platinum-based regimens, but not all patients are.”

According to Dr Goldberg, the results show “that there is less toxicity with pemetrexed/cisplatin, and it has an easier schedule than etoposide/cisplatin. But you have to factor in the financial toxicity of pemetrexed/cisplatin, even though this is hard to do with an individual patient.”

She said the jury is out regarding the need for consolidation therapy to be used in both arms of the trial, but that retrospective studies suggest it is not necessary. “Consolidation therapy is being used less and less.”

PROCLAIM enrolled 598 patients with previously untreated stage III unresectable nonsquamous NSCLC who were randomized to Arm A or Arm B. The patients whose disease did not progress continued with consolidation therapy. The study was closed in August 2012 because of a futility analysis.

The median overall survival was 26.8 months for the pemetrexed group and 25 months for the etoposide group. The 2-year survival rate was 52% in both arms; the 3-year survival rates were 40% with pemetrexed and 37% with etoposide. A subgroup analysis failed to show any preferential benefit for any subgroup in either arm.

Some differences in toxicity favored pemetrexed plus cisplatin. The difference was primarily driven by higher rates of neutropenia, thrombocytopenia, and alopecia in Arm B.

Dr Goldberg said that although both regimens in the study are “reasonable,” better treatments are needed to improve the median overall survival with platinum-based doublets. Hopes are currently riding on the promise of immunotherapy in lung cancer, she added.

Related Items
Immunotherapy Moving into Earlier Lines of Lung Cancer Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Lung Cancer
Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Lung Cancer
Ibrutinib-Related Atrial Fibrillation: An Anticoagulant Challenge
Zain Al-Jammali, PharmD, Brent Beckner, PharmD, Joseph Bubalo, PharmD, BCPS, BCOP
JHOP - June 2019 Vol 9, No 2 published on April 5, 2019 in Online First, Symptom Management
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Web Exclusives published on March 22, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
Atezolizumab plus Chemotherapy New First-Line Regimen for Small-Cell Lung Cancer
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Lung Cancer
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer
Web Exclusives published on October 9, 2018 in Lung Cancer
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Lung Cancer
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lung Cancer
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Lung Cancer
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Gynecologic Cancers, Online First
Last modified: November 18, 2015